It could blight the lives of 350,000 people. Could YOU have 'new' type 1.5 diabetes?

New NHS figures revealed UK hospitals are being overrun by 1.7million type 2 diabetes admissions every year. Close to 10 per cent of people with type 2 diabetes could in fact have type 1.5.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

TYPE 1 and type 2 diabetes are two well established conditions that affect a person ’s blood sugar control. But another type of diabetes, type 1.5 diabetes, is beginning to gain traction - what is it, and are you at risk?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Insofar as either type 1 diabetes or type 2 diabetes increase the burden of senescent cells, we might say that the condition literally accelerates aging. The accumulation of lingering senescent cells is a contributing cause of aging; these errant cells disrupt tissue function and produce the characteristic profile of chronic inflammation known as inflammaging via a potent mix of secreted molecules and vesicles. Diabetic patients suffer more and worse gum disease, periodontitis, than their healthy peers, and researchers here show that hyperglycemia leads to increased numbers of senescent cells in gum tissue, causing all of ...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
CONCLUSION: Fanconi syndrome is a rare, exogenously acquired disorder in adults that often develops as an adverse effect of medication therapy. Our patient presented with Fanconi syndrome as a complication of canagliflozin use for the treatment of presumed type 2 diabetes. She was then started on subcutaneous insulin monotherapy for the treatment of type 1 diabetes mellitus. PMID: 31724039 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - Category: Drugs & Pharmacology Authors: Tags: Am J Health Syst Pharm Source Type: research
AbstractAims/hypothesisThe conserved hypoxia inducible factor 1 α (HIF1α) injury-response pro-survival pathway has recently been implicated in early beta cell dysfunction but slow beta cell loss in type 2 diabetes. We hypothesised that the unexplained prolonged prediabetes phase in type 1 diabetes may also be, in part, due to activation of the HIF1α signallin g pathway.MethodsRNA sequencing (RNA-Seq) data from human islets with type 1 diabetes or after cytokine exposure in vitro was evaluated for activation of HIF1 α targets. This was corroborated by immunostaining human pancreases from individuals ...
Source: Diabetologia - Category: Endocrinology Source Type: research
This study compared extracted structured EHR data to chart review from endocrinologists’ healthcare records at a large, academic ambulatory hospital in Ontario, Canada.MethodsConsecutive chart review for the first 10 patients with either type 1 or type 2 diabetes seen between January 1st, 2015 and March 1st, 2016, were sampled for each of the 10 endocrinologists within the diabetes program, and electronic data extraction was also completed for a core set of structured diabetes care elements. Fischer Exact test was used to determine differences in data availability between extracted EHR data to chart review.ResultsOut...
Source: Canadian Journal of Diabetes - Category: Endocrinology Source Type: research
AbstractPurpose of ReviewIndividuals with type 1 and type 2 diabetes mellitus (T1DM, T2DM) have an increased risk of bone fracture compared to non-diabetic controls that is not explained by differences in BMD, BMI, or falls. Thus, bone tissue fracture resistance may be reduced in individuals with DM. The purpose of this review is to summarize work that analyzes the effects of T1DM and T2DM on bone tissue compositional and mechanical properties.Recent FindingsStudies of clinical T2DM specimens revealed increased mineralization and advanced glycation endproduct (AGE) concentrations and significant relationships between mecha...
Source: Current Osteoporosis Reports - Category: Orthopaedics Source Type: research
Conclusions/interpretationOur study indicates that incident diabetes in adults has an element of autoimmune aetiology. Thus, there might be a reason to re-evaluate the present subclassification of diabetes in adulthood.
Source: Diabetologia - Category: Endocrinology Source Type: research
Publication date: Available online 9 November 2019Source: Journal of Molecular BiologyAuthor(s): Eckhard Lammert, Peter ThornAbstractThe islets of Langerhans or pancreatic islets are pivotal in the control of blood glucose and are complex micro-organs embedded within the larger volume of the exocrine pancreas. Humans can have ∼3.2 million islets [1] which, to our current knowledge, function in a similar manner to sense circulating blood glucose levels and respond with the secretion of a mix of different hormones that act to maintain glucose concentrations around a specific set point [2]. At a cellular level the control...
Source: Journal of Molecular Biology - Category: Molecular Biology Source Type: research
Abstract Although metformin (Met) is the most recommended anti-diabetogenic drug in type 2 diabetic state, the drug is known to compromise bone integrity. Like metformin, omega-3 fatty acids (ω-3) have gluco-regulatory action; however, it aids bone health. Therefore, the present study investigated the effects of ω-3 and/or metformin in diabetic rats. Fifty rats of ten animals per group were divided into the following: Control; Diabetic untreated; Diabetic + ω-3; Diabetic + metformin (metfm) and Diabetic + ω-3 + metf groups. Diabetes was induced by the administration of streptozotocin (6...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Tags: Biomed Pharmacother Source Type: research
All people with type 1 diabetes (T1D) need insulin to survive, with the hope to cut or slow down the devastating long-term micro and macrovascular complications. About one fourth of people with type 2 diabetes (T2D) uses insulin, either as the only antyhyperglycemic drug, or in combination with other glucose-lowering medications [1,2]. Every day, about 6 million diabetic people in the U.S. inject insulin to control their hyperglycemia.
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research
More News: Diabetes | Diabetes Type 1 | Diabetes Type 2 | Endocrinology | Health | Hospitals